Provided by Tiger Trade Technology Pte. Ltd.

Cognition Therapeutics, Inc

1.06
+0.06036.03%
Pre-market: 1.060.00000.00%04:14 EST
Volume:973.71K
Turnover:1.02M
Market Cap:93.57M
PE:-2.26
High:1.08
Open:1.00
Low:0.9998
Close:0.9997
52wk High:3.83
52wk Low:0.2223
Shares:88.27M
Float Shares:87.73M
Volume Ratio:0.83
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.8600
ROE:-109.73%
ROA:-78.99%
PB:2.56
PE(LYR):-1.23

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Netflix, FirstCash Holdings, CF Bankshares

Reuters
·
Feb 06

BRIEF-Cognition Therapeutics Extends Expanded Access Program For Zervimesine (Ct1812) In Dementia With Lewy Bodies

Reuters
·
Feb 05

Cognition Therapeutics Completes Type C Meeting With FDA for Zervimesine (Ct1812) in Dementia With Lewy Bodies

THOMSON REUTERS
·
Jan 27

Cognition Therapeutics Reports Phase 2 Results Showing Zervimesine Slows Progression of Dementia with Lewy Bodies

Reuters
·
Jan 06

Cognition Therapeutics Inc - Company Terminates Previous Sales Agreement With B. Riley - SEC Filing

THOMSON REUTERS
·
Dec 19, 2025

Cognition Therapeutics: Entered Into Open Market Sales Agreement With Jefferies for Offering of up to $75 Mln Shares of Common Stock

THOMSON REUTERS
·
Dec 19, 2025

Cognition Therapeutics Inc - to Offer up to $300 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Dec 19, 2025

Cognition Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 04, 2025

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

GlobeNewswire
·
Dec 03, 2025

Cognition Therapeutics Announces Phase 3 Trials of Zervimesine for Mild-to-Moderate Alzheimer's Disease

Reuters
·
Dec 01, 2025

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (Ct1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (Ctad) Conference

THOMSON REUTERS
·
Dec 01, 2025

B. Riley Raises Price Target on Cognition Therapeutics to $3 From $2, Keeps Buy Rating

MT Newswires Live
·
Nov 21, 2025

Cognition Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.

Dow Jones
·
Nov 19, 2025

Cognition Therapeutics (CGTX) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Nov 19, 2025

Mesoblast Appoints James O'Brien CFO

MT Newswires Live
·
Nov 17, 2025

BUZZ-Mesoblast's Australian shares climb as O'Brien becomes finance chief of US division

Reuters
·
Nov 17, 2025

Cognition Therapeutics Completes Enrollment in Phase 2 Trial of Zervimesine for Early Alzheimer’s Disease

Reuters
·
Nov 13, 2025

Cognition Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Cognition Therapeutics Q3 net loss narrows as trials ending lower R&D costs

Reuters
·
Nov 06, 2025

Cognition Therapeutics Q3 EPS $(0.06) Beats $(0.09) Estimate

Benzinga
·
Nov 06, 2025